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Abstract
Improving access and rational use of psychotropic medications in low- and middle-income coun-
tries is an important factor in reducing the public health burden resulting from mental illness. This 
article considers each component of the medications management cycle to identify current barriers 
to improvement. Selection is hindered by lack of up to date local essential drugs lists whilst pro-
curement and distribution can be affected by the type of system used: centralised or decentralised, 
government-run or independent, push or pull. Rational use involves patients, prescribers and poli-
cy-makers and requires consideration of who is able to prescribe, how prescribing decisions are 
made and how to ensure patient-centred care. We include a number of recommendations based 
on these issues, whilst emphasising the importance of ensuring the broader context of mental ill-
ness and its management is not overlooked when improving access to psychotropic medications.
Key words: access, use, psychotropic medications, low-and middle-income countries
Introduction
 
Mental and substance misuse disorders account for the greatest number of years lived with disabil-
ity (DALYs) globally (Whiteford et al., 2013). In recent years, a growing evidence base has led to 
widespread recognition of these disorders as a significant public health issue in low- and middle-
income countries (Patel, 2007a). The World Health Organisation (WHO) has highlighted the role 
for both psychosocial and pharmacological interventions in the management of mental illness 
(WHO, 2001 and 2011a). However in many low- and middle-income countries government-funded 
psychosocial interventions are almost non-existent, and pharmaceutical therapies therefore often 
form the mainstay of treatment (Raja et al., 2015). Consequently, limited access to psychotropic 
medications may significantly contribute to the public health burden of untreated mental disorders. 
It is estimated that approximately four in five people in need of mental health or neurological care 
in low- and middle income countries do not receive it, and of those who do, the care received is 
often not evidence-based (WHO, 2011a).
Few would argue against the suggestion that health systems in low- and middle-income countries 
should aspire towards a comprehensive bio-psycho-social approach to the management of mental 
disorders (Engel, 1977). It is also notable that psychosocial as well as biological interventions have 
been demonstrated to be effective in low- and middle-income countries (Patel et al., 2007b). In 
fact, an over-reliance on medication prescribing may create a false economy, considering this is 
likely to require access to more highly trained health workers, a relatively expensive resource in 
short supply. There is also a danger that by solely improving access of psychotropic medications in 
areas where psychosocial interventions are unavailable, symptoms may be inappropriately med-
icalised and people with mental illness may be subjected to unnecessary side effects. Therefore 
this article focuses on recommendations for improving access to psychotropic medications strictly 
in the context of advocating for improved overall care for people with mental illness. This would 
preferably be in the form of a stepped care approach, in which only the more severe illnesses 
would require biological treatments.
There are various determinants of access, a term that embodies the concepts of “availability” as 
well as “affordability” (Raja et al., 2015). Although the private sector can often play a significant role 
in the provision of psychotropic medications particularly when no alternative exists, we focus here 
on access and rational use via the public sector.
Access to all medications in the public sector remains limited (WHO, 2011b). Psychotropic medica-
tions however are subject to further challenges. The reputation of psychotropic medications as 
having a potential for dependence and abuse can lead to additional national regulation (WHO, 
2005). Although this regulation may be necessary in certain circumstances, it should be noted that 
most medications for the treatment of common mental disorders have little dependence potential. 
The medications that do have properties that may create dependence, such as the benzodi-
azepines, are not recommended as first line for any mental disorder (NICE, 2011). There is there-
fore a risk that excessive caution and stigmatisation may negatively impact on people receiving 
useful treatment.
Internationally, access can be limited via the Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPS), which introduced a twenty year patent protection for new medications. In 
order to allow exemption from patent protection, countries which may otherwise be unable to afford 
certain medications, may obtain a compulsory license in emergency or life-threatening situations. 
Psychotropic medications however, often may not fulfil the criteria for emergency or life-threatening 
treatment. The decision for governments to fund medications in low- and middle-income countries 
can also frequently be a difficult one, due to the lack of local evidence regarding their cost-effec-
tiveness compared with research in higher-income countries (Jack et al., 2014, Patel et al., 2007b).
General characteristics of health systems such as the existence of a comprehensive national men-
tal health plan have been found to be associated with improved access to psychotropic medica-
tions (McBain et al., 2012). In addition the WHO has outlined the following factors in its manual for 
improving access to psychotropic medications: rational selection, affordable pricing, sustainable 
financing and reliable health and supply systems (WHO, 2005). To deconstruct the issues of ac-
cess and rational use further in this article, we focus on the medicines management cycle in the 
form of selection, procurement, distribution and use.
Selection of psychotropic medications
To ensure rational selection of medications where funding is limited, the WHO produces a biennial 
Model List of Essential Medicines (WHO, 2013). The choice of medications included is based on 
safety, efficacy and cost-effectiveness, and disease prevalence. Together the medications included 
should fulfil the main healthcare requirements of a population. The WHO also encourages the pro-
duction of national lists in order to ensure that medications selected meet local needs. Almost forty 
years after its introduction, at least four in five countries have adopted a national list of essential 
medications (WHO, 2007). However, the processes by which such lists are updated have received 
criticism (Barbui & Purgato, 2014). In particular, it has been suggested that the standards of the 
applications for inclusion of new psychotropic medications on such lists have been relatively low. 
Specifically, systematic reviews of evidence are often not included in applications and conflicts of 
interest do not have to be declared (Barbui & Purgato, 2014). At a local level the decision-making 
process behind the formation of these lists can also lack transparency (Padmanathan et al., 2014). 
Furthermore the extent to which national lists worldwide include psychotropic medications is un-
known and updates do not always occur regularly (Raja et al., 2015). Even when the above criteria 
are met, psychotropic medications are generally unavailable at primary health centres and often 
unavailable at district-level hospitals (Padmanathan et al., 2014, Raja et al., 2015).
The choice of specific medications included in a number of essential drugs lists is also worth con-
sideration. Diazepam appears to be frequently available at a primary care level, whereas fluoxetine 
(or other selective serotonin re-uptake inhibitors) is often missing from lists or is only available in 
secondary or tertiary centres (Padmanathan et al., 2014, Raja et al., 2015, Wagenaar et al., 2015). 
Yet SSRI’s such as fluoxetine are the first line recommended medications for depressive and anxi-
ety disorders (Patel et al. 2007b), two conditions which make the greatest contribution to the public 
health burden of mental disorders worldwide (Ferrari et al. 2013).
Procurement and distribution of psychotropic medications
Effective procurement refers to obtaining the required quantity and quality of medications at the 
correct time at minimum cost. Factors affecting medication procurement systems include adequate 
funding and the type of procurement models. The proportion of budgets allocated for psychotropic 
medications vary between countries. However, due to the low priority often given to mental health, 
funding is often inadequate. In Ghana, for example, donations account for a significant proportion 
of funding for psychotropic medications (Raja et al., 2010).
India provides us with a good example of the outcomes resulting from different medication pro-
curement systems due to the variability of systems between each state. A study which compared 
medication procurement systems in five states, found that centralised autonomous organisations 
were most efficient (Singh et al., 2012). The procurement process itself is also important. Pull sys-
tems in which health care facilities submit orders or estimates, are generally considered more ef-
fective at meeting local needs than push systems where standardised quantities of medications 
are distributed without consideration of feedback (Raja et al., 2015). Pull systems however rely on 
accurate documentation, which can often be hindered by a lack of technology and trained person-
nel. In Bihar in India for example, in one particular year the total consumption figures documented 
were five times the budgeted cost (Padmanathan et al., 2011). In contrast, in Kerala and Tamil 
Nadu a computer system has been used to monitor stock levels with more success (Singh et al., 
2012).  Furthermore, transparency and quality assurance are also vital aspects of any procurement 
system (Singh et al., 2012). 
The lack of availability of psychotropic medications outside tertiary hospitals is often partly hin-
dered by distribution issues. Most notably the small quantities of medications prescribed at a local 
or district level may not be profitable for individual companies to deliver (Padmanathan et al. 2014). 
This issue may be overcome with a centralised procurement and distribution system. 
Small-scale Drug Resolving Funds, in which medications are sold at almost cost-price with the 
payment then re-invested into further medications, have been set up in areas where government 
funded medications are unavailable in order to improve access (Eaton, 2008). However, even if 
sold at cost price, such costs can often limit access to medications for the poorest, unless this is 
specifically addressed. In addition the small-scale nature of these projects may result in inefficien-
cies along the supply chain and may therefore be difficult to sustain in the long term.
Use of psychotropic medications
Rational use of any medication refers to ensuring the correct type and dose of a drug is prescribed 
and taken for the correct duration at the least cost to the community. Irrational use can have a 
harmful effect on both the individual and the community due to the iatrogenic and financial conse-
quences. Numerous reasons exist for irrational use of psychotropic medications, including cultural 
norms, financial incentives, lack of education and inadequate regulation. Addressing these requires 
initiatives involving all stakeholders: patients, prescribers and regulatory bodies.
Decisions regarding who should prescribe psychotropic medications are one major issue when 
considering rational use. The current movement to scale up mental health care and eliminate the 
treatment gap encourages use of non-specialist health workers to deliver interventions. In a recent 
systematic review, eight publications detailed interventions in which non-specialists were trained to 
provide pharmacotherapy (van Ginneken et al., 2013). However in Bihar in India for example cul-
tural norms as well as government restrictions often prevent such workers prescribing (Pad-
manathan et al., 2014). This was emphasised in a systematic review of the acceptability and feasi-
bility of using non-specialist health care workers to provide mental health care; specialists ex-
pressed scepticism regarding task-sharing (Padmanathan et al., 2013). Although specialists may 
have genuine concerns about ensuring patient safety, a monopoly on prescribing may create con-
flicts of interest. It would be in a specialist’s best interests to limit those able to issue prescriptions. 
Nonetheless several recent studies have demonstrated that it is possible to overcome the initial 
scepticism amongst specialists about the provision of mental healthcare by non-specialists, by en-
suring regular communication between all stakeholders (Padmanathan et al., 2013).
A second issue relates to how prescribing decisions should be made. Ideally, decisions would be 
independent and based on up to date evidence. This would rely on ensuring no financial incentives 
for unethical practice, such as payment per prescription written, which may lead to excessive use 
of repeat prescriptions. It would also rely on awareness of the limits of clinical acumen and accep-
tance of the important role of evidence-based guidelines (Dua et al., 2011). Although contextualisa-
tion of current guidelines is necessary, they are essential to allow transparency in decision-making. 
Guidelines also ensure decisions take into account up to date information regarding efficacy and 
cost-effectiveness without being unduly influenced by pharmaceutical industry incentives (WHO, 
2012). Furthermore they can also be used to assist non-specialist health workers in prescribing.
Adherence in the form of both over- and under-use is a key issue from a patient perspective, with a 
meta-analysis finding that patients with mental illness often take less than half the prescribed 
quantity of medications (Cramer & Rosenbeck, 1998). The reasons for this could be numerous. 
They include stigma associated with mental illness and its treatment, difficulty in travelling to a 
place where medications are accessible, the financial burden associated with buying medications, 
side effects associated with medications and failure of symptoms to improve (Pareek et al., 2013, 
Teferra et al., 2013). A number of the practical barriers could be removed by improving access to 
psychotropic medications. However patient involvement in consultations is also vital to ensure cor-
respondence between the patient and prescriber’s expectations and understanding of the medica-
tions prescribed. Consequently the WHO recommends measuring consultation and dispensing 
times as well as patients’ knowledge of the correct dosage when assessing rational use (WHO, 
1993).
Recommendations  
Recommendations for research in low- and middle-income countries:
1. Assessment of cost-effectiveness of psychotropic medications.
2. Assessment of local psychotropic drug distribution systems using both quantitative and qualita-
tive methods in order to identify specific areas for improvement.
3. Local contextualisation of prescribing guidelines.
4. Evaluation of acceptability and feasibility of prescribing psychotropic medication amongst 
trained non-specialist health workers. 
5. Assessment of patient’s views regarding acceptability and adherence to psychotropic medica-
tions.
Recommendations for policy:
1. A local essential drugs list produced and updated regularly through a transparent, independent, 
evidence-based process.
2. A pull procurement system developed with procedures to ensure careful documentation of 
medications dispensed to enable procurement of the correct type and quantity of medications.
3. Funding allocated by governments specifically for essential psychotropic medications.
Recommendations for practice:
1. Increase use of guidelines when making prescribing decisions.
2. Ensure patient understanding of medications prescribed, likely duration required and impor-
tance of adherence.
3. Regular monitoring of patients taking psychotropic medications, rather than indefinite repeat 
prescriptions without reassessment. 
4. Consequences of prescriber payment methods to be carefully considered. Payment methods 
should not incentivise unethical practice.
5.   Use of an active regulatory body to monitor prescribing practices.
Conclusion
 
Access to psychotropic medications is essential in order to address the public health burden at-
tributable to untreated mental illnesses. In general further research, implementation of policy and 
changes to practice are required to address issues regarding drug selection, procurement, distribu-
tion and use. National or district-level assessment of the medications management cycles is how-
ever necessary in order to identify which, if any, of these barriers are locally relevant. 
Yet it is important to once again stress that improving access to psychotropic medications should 
not absolve governments of responsibility for the provision of alternative interventions to treat men-
tal illness. To reiterate a recent editorial in this journal (De Silva et al., 2015): mental health and 
sustainable development are deeply intertwined and therefore it is important that the broader con-
text is not overlooked when improving access to psychotropic medications.
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